Clinical Trial Update: Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating murlentamab (GM102) anti-tumoral activity in colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• murlentamab (GM102) (murlentamab)

Snippet

Sponsor: GamaMabs Pharma | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED